Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | GLA | P06280 | 5/20 | 0.33 |
| ▸ | GAA | P10253 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897324 | 0.92 | CRHR1 (0.33) | HSD17B13GRIA2GRIN2APIM1PIM3 | |
| SCHEMBL7897177 | 0.91 | HSD17B13 (0.35) | HSD17B13ALDH1A1GRIA2GRIN2APIM1 | |
| SCHEMBL7899042 | 0.89 | HSD17B13 (0.35) | HSD17B13KDM4EGLAGAAALDH1A1 | |
| SCHEMBL7902745 | 0.87 | KDM4E (0.37) | HSD17B13KDM4EGLAGAAALDH1A1 | |
| SCHEMBL7896827 | 0.84 | TSHR (0.36) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL3467749 | 0.84 | HSD17B13 (0.37) | HSD17B13ALDH1A1MEN1KMT2APIM1 | |
| SCHEMBL7903480 | 0.84 | CHEK1 (0.46) | HSD17B13KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL7906217 | 0.83 | TP53 (0.39) | HSD17B13KDM4EGLAGAAALDH1A1 | |
| SCHEMBL7896811 | 0.83 | KDM4E (0.37) | KDM4EGLAGAAALDH1A1HPGD | |
| SCHEMBL7895830 | 0.83 | HSD17B13 (0.36) | HSD17B13PIM1PIM3PIM2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379510-B1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LTD (AU) | 2016-10-26 | — | — | EP | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-12-17 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-9145375-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-09-29 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-8889695-B2 | Quinazolinone compounds | PRANA BIOTECHNOLOGY LIMITED (AU) | 2014-11-18 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-02-16 | — | — | US | disclosed |
| WO-2010071944-A1 | QUINAZOLINONE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359796-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NDUFV2 | HSD17B13 2537/4885KDM4E 3990/4885GLA 1862/4885 |
| US-20150025072-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | HSD17B13 2552/4885KDM4E 3927/4885GLA 1857/4885 |
| US-20120040980-A1 | QUINAZOLINONE COMPOUNDS | PARK7, SNCA, NQO2 | HSD17B13 2552/4885KDM4E 3927/4885GLA 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.